Clinical Development Setbacks, Pricing Pressures Hit Roche
Executive Summary
Recent setbacks for two of its most important pipeline projects, as well as a tougher pricing environment in key Western countries, will take a toll on Roche in 2010 and beyond, company executives told analysts during a half-year earnings call on July 22
You may also be interested in...
Roche Announces Internal Review Likely To Result In Staff, Program Cuts
Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27